תאריך רישום: April 24, 1983

מסלול הגשה: מולקולה חדשה

יצרן: ALMIRALL HERMAL GMBH, GERMANY

בעל רישום: NEOPHARM LTD

D10AF02 :ATC Code

4.1 Therapeutic indications All forms of acne, in particular inflammatory forms with papules and pustules.

תאריך רישום: January 20, 1999

מסלול הגשה: מולקולה חדשה

יצרן: JANSSEN PHARMACEUTICA N.V, BELGIUM

בעל רישום: J-C HEALTH CARE LTD

N05AX08 :ATC Code

Therapeutic Indications RISPERDAL is indicated for the management of schizophrenia, and the manifestations of psychotic disorders. The antipsychotic efficacy of Risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic in-patients. RISPERDAL is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. RISPERDAL is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated- aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. RISPERDAL is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors.

תאריך רישום: September 3, 2003

מסלול הגשה: מולקולה חדשה

יצרן: EXCELLA GMBH & CO. KG, GERMANY

בעל רישום: PADAGIS ISRAEL AGENCIES LTD, ISRAEL

L01AB01 :ATC Code

4.1 Therapeutic Indications For the palliative treatment of chronic granulocytic leukaemia (also called chronic myeloid leukaemia).

תאריך רישום: March 14, 1999

מסלול הגשה: מולקולה חדשה

יצרן: SANOFI WINTHROP INDUSTRIE, FRANCE

בעל רישום: PHARMASHALOM

R06AX25 :ATC Code

4.1 Therapeutic indications Mizolastine is a long acting H1- antihistamine indicated for the symptomatic treatment of seasonal allergic rhinoconjunctivitis (hay fever), perennial allergic rhinoconjunctivitis and urticaria.

תאריך רישום: January 5, 2004

מסלול הגשה: מולקולה חדשה

יצרן: N.V. ORGANON, THE NETHERLANDS

בעל רישום: ORGANON PHARMA ISRAEL LTD., ISRAEL

G03AC09 :ATC Code

4.1 Therapeutic indications Contraceptive.

תאריך רישום: February 17, 2014

מסלול הגשה: מולקולה חדשה

יצרן: FAREVA MIRABEL, FRANCE

בעל רישום: MERCK SHARP & DOHME (ISRAEL - 1996) COMPANY LTD, ISRAEL

J01XX09 :ATC Code